Jacobs joins GE Healthcare as developer of Pfizer's China mAb plant

By Gareth Macdonald

- Last updated on GMT

Pfizer China single-use plant collaboration between Jacobs and GE

Related tags Ge healthcare Biotechnology

Jacobs Engineering Group has been contracted to collaborate with GE Healthcare on the development of Pfizer’s $350m monoclonal antibody manufacturing centre in Hangzhou, China.

Under the contract, the US engineering firm will be responsible for overall site design include the development of fill/finish and utility buildings a quality laboratory, an office building and a warehouse.

Jacobs will work with GE Healthcare, which was hired by Pfizer to develop the monoclonal antibody (mAb) facility in June​. The General Electric division will provide single-use bioreactors with associated downstream tech as part of its KUBio modular facility system.

Daria Donati, Global Head of Evaluation & Offering, Enterprise Solutions, GE Healthcare Life Sciences, said: “We are already working collaboratively with Jacobs and other partners to help deliver to Pfizer’s overall vision for local biomanufacturing capacity to serve the growing China market​.”

Donati added that: “The design of our KUBio facility is ideally suited to integration into larger projects”​ citing the facility GE developed for JHL Biotech​ in Wuhan, China as an example.

Jacobs has provided engineering services for firms in a variety of industries.

Previous projects with pharmaceutical companies include the development of a Porton Fine Chemicals’ plant​ in Chongqing, China. More recently​ Jacobs was hired to develop a facility by RNAi drug maker Alnylam.

Related topics Downstream Processing Facilities

Related news

Show more

Related products

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Related suppliers

Follow us


View more